Abstract
ABSTRACT
Background
Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical location, resulting in diagnosis at advanced stages and limited treatment options. Consequently, patients often experience poor prognosis with low 5‐year survival rates. Clinical and translational studies have demonstrated marked biological heterogeneity in GBC, primarily driven by diverse molecular alterations that fuel tumor initiation and progression.
Methods
In the present study, we investigated recurrently mutated genes in GBC using The Cancer Genome Atlas (TCGA) and Catalogue of Somatic Mutations in Cancer (COSMIC) gallbladder cohorts, focusing on genes with a mutation frequency above a pre‐specified threshold (≥ 5% in at least one dataset). We then cross‐referenced these genes with published literature till date in GBC and other solid tumors where the same variants have been functionally characterized as loss‐of‐function or gain‐of‐function. “Likely loss of function” was assigned only when mutations were annotated in OncoKB/COSMIC as truncating/nonsense or as missense variants with experimental or strong computational evidence of functional impairment.
Results
Evaluation and the functional impact of prominent mutations viz. TP53, SMAD4, PIK3CA, CDKN2A, ARID1A, ARID2, KRAS, ELF3, ERBB3, ERBB2, STK11, and CTNNB1 on key cellular signaling pathways that regulate GBC initiation and progression. These alterations influence various oncogenic mechanisms, including cell proliferation, survival, apoptosis evasion, and metastatic potential, by disrupting pathways. By comparing the mutational patterns observed in GBC with those reported in other malignancies sharing analogous molecular signatures, we delineate potential therapeutic vulnerabilities.
Conclusions
Mutation‐guided therapeutic approaches hold great promise for advancing precision medicine in GBC. By tailoring treatments to the specific molecular alterations driving tumor development, this could pave the way for more effective interventions and improved patient outcomes in a disease long constrained by limited therapeutic options.